HomeNewsBusinessMarketsAdopt bottoms-up approach; Sun Pharma a good buy: Pros

Adopt bottoms-up approach; Sun Pharma a good buy: Pros

Despite the fall in Sun Pharma on the back of Monday's profit warnings, Parag Thakkar of HDFC Securities and Devang Mehta of Anand Rathi Financial Services advise investors to buy the stock and understand that the integration with Ranbaxy will take its own time. From a 18-24 months perspective, it is a great buy, says Mehta.

July 21, 2015 / 16:29 IST
Story continues below Advertisement

Your browser doesn't support HTML5 video.

The Sensex closed 237.98 points down or 0.84 percent at 28182.14, and the Nifty ended 74.00 points lower or 0.86 percent at 8529.45 in trade on Tuesday. But the most interesting point about today's trade remains the intraday rise in Infosys (11.05 percent) and the fall in Sun Pharma (-14.95 percent), respectively.

Despite the fall in Sun Pharma on the back of Monday's profit warnings, Parag Thakkar of HDFC Securities and Devang Mehta of Anand Rathi Financial Services advise investors to buy the stock and understand that the integration with Ranbaxy will take its own time. From a 18-24 months perspective, it is a great buy, says Mehta.

Story continues below Advertisement

Thakkar says Infosys too was a great buy a few days ago, while adding that it is no time to sell the stock.

Both Mehta and Thakkar also like Asian Paints. While the stock fell 4.14 percent in trade today, HDFC Securities believes it to be a great company.